Dublin, July 25, 2023 (GLOBE NEWSWIRE) -- The "Eylea Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers, and senior ...

Aflibercept, the generic name for Eylea, is indicated to improve eyesight in patients with nAMD and other specific neovascular retinal diseases. Biosimilars are essentially cut-rate generic ...

Eylea, indicated for eye disorders such as wet age-related macular degeneration, generated $2.9B in sales from Europe in 2023, making up nearly half of the drug's global sales.

Bayer said in a statement the European Medicines Agency recommended that eye drug Eylea, at a high dose of 8 mg, can be injected at intervals of up to six months to treat wet age-related macular ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

U.S. sales of the drug, Eylea, increased 27% to $831 million, compared with $655 million in the prior-year quarter.

(Corrects paragraph 3 to say Roche's Vabysmo was approved in 2022, not last year) Jan 8 (Reuters) - Regeneron Pharmaceuticals on Monday reported eye drug Eylea's fourth-quarter U.S. preliminary ...

FRANKFURT, Nov 10 (Reuters) - Bayer (BAYGn.DE), opens new tab said on Friday that the European Medicines Agency recommended approval of a higher dose version of eye drug Eylea for treatment of a ...

boosted by strong demand for a new formulation of its blockbuster eye drug Eylea. The company also announced a new quarterly cash dividend and boosted its share-buyback program by $3 billion ...

The FDA did not approve the supplemental biologics license application for Eylea HD. The application would have added extended dosing intervals greater than 16 weeks, if approved. Editor’s note ...

Novartis's generics arm Sandoz is set to enrol patients with neovascular age-related macular degeneration (nAMD) in a late-stage trial of a biosimilar version of Bayer and Regeneron's Eylea ...